• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Effects of 4-hydroxy-4-androstene-3, 17-dione and 10-propargylestr-4-ene-3, 17-dione on the metabolism of androstenedione in human breast carcinoma and breast adipose tissues.

作者信息

Perel E, Davis S P, Covey D F, Killinger D W

出版信息

Steroids. 1981 Oct;38(4):397-405. doi: 10.1016/0039-128x(81)90074-x.

DOI:10.1016/0039-128x(81)90074-x
PMID:7314156
Abstract

The effects of 4-hydroxy-4-androstene-3, 17-dione (4-OH-A) and 10-propargylestr-4-ene-3, 17-dione (PED) on the aromatization of androstenedione (A) and the conversion of A to testosterone (T) were studied in incubations with breast carcinoma and breast adipose tissues. Parallel studies were carried out to determine the effects of 4-OH-A and PED on A metabolism in tissue from 5 patients with breast carcinoma. At 11 micro M, both compounds fully inhibited aromatization, whereas the conversion of A to T was decreased in only 2 incubations. Studies with varying concentrations of 4-OH-A and PED demonstrated that both compounds inhibited estrone (E1) formation by 80% at a concentration of 0.085 micro M, with maximum effect at 0.34 micro M. 90% inhibition of estradiol (E2) formation was observed at inhibitor concentrations of 0.17 micro M or greater. T formation was slightly affected at 0.67 microM, but was progressively inhibited with increasing 4-OH-A or PED concentrations, reaching 70% at 11 micro M. Similar experiments with 4-OH-A in breast adipose tissue homogenates showed that a concentration of 0.1 micro M was sufficient to inhibit aromatization while T inhibition required 11 micro M. 4-OH-A and PED are selective inhibitors of aromatization in human breast tissues and may provide a mechanism for controlling estrogen responsive processes.

摘要

相似文献

1
Effects of 4-hydroxy-4-androstene-3, 17-dione and 10-propargylestr-4-ene-3, 17-dione on the metabolism of androstenedione in human breast carcinoma and breast adipose tissues.
Steroids. 1981 Oct;38(4):397-405. doi: 10.1016/0039-128x(81)90074-x.
2
Comparative studies of aromatase inhibitors in cultured human breast cancer cells.培养的人乳腺癌细胞中芳香化酶抑制剂的比较研究。
Cancer Res. 1982 Aug;42(8 Suppl):3378s-3381s.
3
The effects of in vivo administration of 10-propargylestr-4-ene-3,17-dione on rat ovarian aromatase and estrogen levels.体内给予10-丙炔基雌甾-4-烯-3,17-二酮对大鼠卵巢芳香化酶和雌激素水平的影响。
J Enzyme Inhib. 1990;4(2):143-52. doi: 10.3109/14756369009040736.
4
Effect of 1,4,6-androstatriene-3,17-dione (ATD), 4-hydroxy-4-androstene-3,17-dione (4-OH-A) and 4-acetoxy-4-androstene-3,17-dione (4-Ac-A) on the 5 alpha-reduction of androgens in the rat prostate.
J Steroid Biochem. 1986 Oct;25(4):593-600. doi: 10.1016/0022-4731(86)90408-5.
5
Inhibition of growth and appearance of estrogen-dependent rat mammary tumors by 10-propargylestr-4-ene-3,17-dione, an aromatase inhibitor.芳香酶抑制剂10-丙炔基雌甾-4-烯-3,17-二酮对雌激素依赖性大鼠乳腺肿瘤生长和外观的抑制作用
Breast Cancer Res Treat. 1993;26(1):15-21. doi: 10.1007/BF00682696.
6
Inhibition of peripheral aromatization in baboons by an enzyme-activated aromatase inhibitor (MDL 18,962).一种酶激活的芳香化酶抑制剂(MDL 18,962)对狒狒外周芳香化作用的抑制
Endocrinology. 1988 May;122(5):2007-11. doi: 10.1210/endo-122-5-2007.
7
Inhibition of Leydig tumor cell steroidogenesis by 10-propargylestr-4-ene-3,17-dione, an irreversible aromatase inhibitor.不可逆性芳香化酶抑制剂10-丙炔基雌-4-烯-3,17-二酮对睾丸间质细胞瘤细胞类固醇生成的抑制作用
Cancer Res. 1985 Oct;45(10):4883-9.
8
Inhibition of peripheral aromatization by aromatase inhibitors, 4-hydroxy- and 4-acetoxy-androstene-3,17-dione.芳香化酶抑制剂、4-羟基-和4-乙酰氧基-雄烯-3,17-二酮对周围芳香化作用的抑制
Endocrinology. 1980 Jan;106(1):19-21. doi: 10.1210/endo-106-1-19.
9
Inhibition of aromatase activity and of endocrine-responsive tumor growth by 10-propargylestr-4-ene-3, 17-dione and its 17-propionate derivative.
Steroids. 1987 Jul-Sep;50(1-3):135-46. doi: 10.1016/0039-128x(83)90067-3.
10
The metabolism of androstenedione and testosterone to C19 metabolites in normal breast, breast carcinoma and benign prostatic hypertrophy tissue.雄烯二酮和睾酮在正常乳腺、乳腺癌及良性前列腺增生组织中代谢为C19代谢物的过程。
J Steroid Biochem. 1983 Aug;19(2):1135-9. doi: 10.1016/0022-4731(83)90407-7.

引用本文的文献

1
Formestane. A review of its pharmacological properties and clinical efficacy in the treatment of postmenopausal breast cancer.福美司坦。其治疗绝经后乳腺癌的药理特性及临床疗效综述。
Drugs Aging. 1996 Oct;9(4):292-306. doi: 10.2165/00002512-199609040-00006.
2
Formestane. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in the management of breast cancer and prostatic cancer.福美司坦。对其药效学、药代动力学特性以及在乳腺癌和前列腺癌治疗中的潜在应用的综述。
Drugs. 1993 Jan;45(1):66-84. doi: 10.2165/00003495-199345010-00007.